Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting
Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e013636
DOI: 10.1136/jitc-2025-013636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.02.2026. Verfasst von Haoyue Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Receptors, Immunologic, T-Lymphocytes, Regulatory, Antigens, Differentiation, T-Lymphocyte, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Project of MOST, China, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Background
Global clinical programs based on TIGIT (T cell immunoglobulin and ITIM domain) blockade have been terminated due to inadequate clinical efficacy. New approaches are needed to increase the antitumor activity of anti-TIGIT-based immunotherapy.
Methods
Multiomics analyses, including single-cell RNA sequencing (scRNA-seq), single-cell TCR sequencing (scTCR-seq), and The Cancer Genome Atlas bulk RNA-seq, were performed to profile TIGIT and the costimulator CD226 expression and assess intratumoral regulatory T cells (Tregs) clonality, with validation by flow cytometry in murine and patient-derived tumor-infiltrating lymphocytes. The therapeutic efficacy of anti-TIGIT antibodies (αTIGIT), including αTIGIT-IgG1-wild-type (WT), αTIGIT-IgG1-WT with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity (αTIGIT-IgG1-ADCC), αTIGIT-IgG4-WT, and tiragolumab, was evaluated in MC38 tumors-inoculated humanized TIGIT knock-in mice ( Tigit h/h , Tigit h/m ). Tumor microenvironment alterations were analyzed using flow cytometry and scRNA/TCR-seq. Antibody binding affinity and ADCC activity were assessed via biolayer interferometry and in vitro ADCC assays. Safety profiles were examined in a murine immune-related adverse events model through growth monitoring, survival analysis, and histopathological evaluation.
Results
Using mouse models and clinical sample analysis, we identified a population of TIGIT high CD226 − clonally expanded intratumoral Tregs as a major barrier limiting the ability of TIGIT blockade to enhance effector cell function. αTIGIT-IgG1-ADCC specifically targeted and eliminated the TIGIT high CD226 − clonally expanded Treg subset, resulting in a marked improvement in antitumor efficacy compared with WT and clinically unsuccessful αTIGIT. Mechanistically, removal of these Tregs through αTIGIT-IgG1-ADCC relieved their suppression of stem-like CD4 + T cells, facilitating their differentiation into T helper cell 1 (Th1) effector cells. Th1-derived interferon-gamma (IFN-γ) further enhanced the functionality of tumor-infiltrating CD8 + T cells. Importantly, the presence of clonally expanded intratumoral Tregs and the suppression of stem-like CD4 + T cells correlated with poor immunotherapy response in patients with non-small cell lung cancer.
Conclusions
Targeted elimination of clonally expanded intratumoral Tregs is essential to unlock the full therapeutic potential of αTIGIT. These novel findings provide a key rationale and strategic direction for overcoming the limitations of current αTIGIT-based cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- AcroImmune Biopharmaceutical, Nanjing, China.
- OncoC4, Rockville, Maryland, USA.
- Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China zhy3331a@shsmu.edu.cn lvwei@sinh.ac.cn lihecheng2000@hotmail.com zhang…
- Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China zhy3331a@shsmu.edu.cn lvwei@sinh.ac.cn lihecheng2000@hotmail.com zhangpengdyx@163.com.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Project of MOST, China
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Zhou, H., Li, J., Mei, S., Zhang, M., Zhao, H., Yan, K., Cheng, Y., Zhou, Q., Zheng, P., Liu, Y., Zhang, P., Li, H., Lu, W., & Zhang, Y. (2026). Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. Journal for ImmunoTherapy of Cancer, 14(2), e013636. https://doi.org/10.1136/jitc-2025-013636
Vancouver
Zhou H, Li J, Mei S, Zhang M, Zhao H, Yan K, et al. Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. Journal for ImmunoTherapy of Cancer. 2026;14(2):e013636. doi:10.1136/jitc-2025-013636
BibTeX
@article{Zhou2026,
author = {Zhou, Haoyue and Li, Jinmei and Mei, Song and Zhang, Meiyu and Zhao, Haochen and Yan, Kepeng and Cheng, Yumeng and Zhou, Qunmin and Zheng, Pan and Liu, Yang and Zhang, Peng and Li, Hecheng and Lu, Wei and Zhang, Yan},
title = {Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {2},
pages = {e013636},
doi = {10.1136/jitc-2025-013636}
}
EUVIMED